Pharma Review Advertising in India: A Digital Compliance and Campaign Approval Guide for the UCPMP 2024 Era

The Indian pharmaceutical industry crossed an estimated ad spend of roughly ₹4,933 crore in 2025 — and yet, a significant portion of those campaigns were either delayed, pulled, or quietly revised because the review process failed somewhere between the creative brief and the live date. What a lot of people miss is that pharma review advertising is not simply a legal formality; it is the structural backbone that determines whether a campaign reaches its audience at all, or gets buried in a compliance queue for weeks.

We have worked with enough pharma brands — from large multinational companies with offices in Mumbai and Delhi to regional OTC players expanding into Tier 2 cities — to know that the review workflow is where most campaigns either gain or lose their competitive edge. The brands that treat the Medical, Legal, Regulatory process as a creative constraint tend to launch late and spend more; the ones that build it into their planning from day one consistently outperform on both reach and cost efficiency.

What Is Pharma Review Advertising and Why Does It Matter in India?

Pharma review advertising refers to the structured process by which pharmaceutical promotional materials — whether digital banners, eDetailers, paid search ads, social media content, or video campaigns — are evaluated and approved by a combination of internal review panels and external regulatory bodies before they go live. In India, this process is shaped by a uniquely layered regulatory environment, which means that a campaign approved in one format or channel may still require separate review if it is adapted for another.

The stakes are higher than most brand managers initially appreciate. India is one of the few markets where pharmaceutical advertising is governed simultaneously by the Drugs and Magic Remedies Objectionable Advertisements Act of 1954, the Drugs and Cosmetics Act of 1940, the UCPMP 2024 issued by the Department of Pharmaceuticals, guidelines from the ASCI, and increasingly, the Consumer Protection Act 2019 — which gives the Central Consumer Protection Authority real enforcement teeth against misleading advertisements. A campaign that clears one framework may still fall foul of another, which is why end-to-end pharma review advertising workflows have become non-negotiable for any brand operating at scale in India.

At SmartAds, we always tell our clients that pharma review advertising is not a department — it is a discipline. The brands that treat it as a one-time sign-off before launch are the ones who end up calling us at 11 PM the night before a campaign goes live, asking whether a particular claim needs a citation or whether a before-and-after visual technically constitutes a prohibited testimonial. The answer, frankly speaking, is almost always more nuanced than a yes or no.

How Does the MLR Review Process Work in Indian Pharmaceutical Advertising?

The Medical, Legal, Regulatory review process — referred to across the industry simply as MLR review — is the internal gatekeeping mechanism that pharmaceutical companies use to evaluate promotional material before it is submitted to any external body or published on any channel. The MLR review panel typically comprises a medical affairs representative, a legal counsel familiar with pharma advertising law, and a regulatory affairs officer; and in larger organisations, this panel may also include a compliance officer and a market access specialist, each of whom reviews the material from a different risk lens.

What makes the MLR review process particularly consequential in the Indian context is that it operates without a single standardised timeline. We have seen review cycles run as short as five working days for straightforward OTC drug advertising materials and stretch to six weeks or more for prescription drug campaigns involving clinical data, comparative claims, or HCP-targeted eDetailers. The delay is rarely about the content itself; it is almost always about the sequencing — materials submitted without complete references, or without a clear indication of the target audience, tend to bounce back and restart the clock entirely. One pharmaceutical company we worked with in Bangalore lost an entire seasonal campaign window — roughly eight weeks of planned media time — because an eDetailer for a respiratory product was submitted to the MLR review panel without the underlying clinical study citations formatted to the panel's internal standard.

The MLR review process in India is further complicated by the fact that digital advertising formats require separate review passes for each adaptation. A banner ad approved for desktop display is not automatically cleared for mobile, and a video approved for YouTube pre-roll may need a separate review if it is repurposed for WhatsApp pharma marketing or embedded in a programmatic advertising campaign. This is not bureaucratic overreach; it reflects the genuine difference in how audiences interact with each format, and the different regulatory expectations that apply.

What Does UCPMP 2024 Mean for Your Pharma Review Advertising Workflow?

The Uniform Code for Pharmaceutical Marketing Practices 2024 — which replaced the earlier 2015 version and was formally issued by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers — represents the most significant update to India's pharma marketing governance framework in nearly a decade. UCPMP 2024 is not a law in the traditional sense; it is a mandatory code of conduct that pharmaceutical companies operating in India are required to follow, and self-declaration of UCPMP compliance has been made a condition for certain regulatory interactions. The distinction matters because it shapes how the review process is documented and evidenced.

Under UCPMP 2024, pharmaceutical advertising review now requires that all promotional materials — including digital campaigns, social media posts, eDetailers, and paid search advertising — carry accurate, balanced, and up-to-date information that reflects the current approved prescribing information. The fair balance principle, which requires that risk information be presented with the same prominence as benefit claims, has been explicitly extended to digital formats under the 2024 code, which is a change that caught several brands off-guard when they realised their existing digital creative templates were non-compliant. The code also tightens the rules around gifts, hospitality, and CME sponsorship advertising — areas where the intersection of marketing and medical education has historically been ambiguous.

What UCPMP 2024 means practically for your pharma review advertising workflow is that the review panel's checklist has grown longer, and the documentation trail needs to be more explicit. Self-declaration of UCPMP compliance is now expected to be supported by internal audit records, which means that every piece of promotional material — including digital campaigns — needs to be traceable back to an approved claim source. At SmartAds, our media planning team works closely with clients' regulatory affairs teams to ensure that the campaign brief itself is structured in a way that makes the MLR review process faster; we have found that campaigns where the media plan and the compliance documentation are developed in parallel — rather than sequentially — tend to clear review in roughly 40% less time.

Which Regulatory Bodies Govern Pharma Advertising Review in India?

The regulatory framework governing pharmaceutical advertising in India is genuinely multi-layered, which surprises many brand managers who assume that ASCI is the only body they need to satisfy. The CDSCO — the Central Drugs Standard Control Organisation — is the primary statutory authority under the Drugs and Cosmetics Act 1940, and it has jurisdiction over the approval of drug claims and the prohibition of misleading advertisements for scheduled drugs. The DMRA 1954, formally the Drugs and Magic Remedies Objectionable Advertisements Act, prohibits advertising for certain categories of conditions — including epilepsy, cancer, and sexual disorders — regardless of the medium, which means that digital advertising campaigns for products touching these therapeutic areas require especially careful review.

The ASCI operates as a self-regulatory body, but its reach has expanded considerably since its 2023 influencer guidelines for health and wellness were issued — guidelines which have direct implications for pharma brands working with healthcare influencers and patient advocacy communities on social media. The OPPI Code of Pharmaceutical Practices, maintained by the Organisation of Pharmaceutical Producers of India, adds another layer specifically for OPPI member companies, covering HCP engagement, medical samples, and the conduct of clinical studies used in promotional claims. The National Medical Commission has also issued guidelines that affect how pharmaceutical companies interact with healthcare professionals in promotional contexts, which feeds back into the HCP-facing advertising review process.

On top of that, the Consumer Protection Act 2019 has given the Central Consumer Protection Authority the power to take suo motu action against misleading advertisements — and the CCPA has not been shy about using it. Several pharma and wellness brands have received notices under this framework in the past two years, which has made legal review of digital advertising claims significantly more rigorous. The intersection of the Consumer Protection Act 2019 and UCPMP 2024 is an area that most pharma review advertising guides do not adequately address; frankly speaking, it is where the real compliance risk now sits for brands running direct-to-consumer advertising in India.

How Is Pharma Digital Ad Spend Shifting in India in 2025–2026?

India's pharma advertising market is undergoing a structural shift that is visible in the numbers. The FICCI-EY Media and Entertainment Report and the Dentsu e4m Report have both tracked a consistent migration of pharma ad spend from traditional print and television toward digital channels over the past three years; the digital share of pharma advertising in India is now estimated to be somewhere between 28% and 35% of total category spend, which represents a significant acceleration from where the industry was in 2021. Paid search advertising, programmatic advertising, and social media marketing for pharma are the three fastest-growing digital sub-formats, driven by the ability to target healthcare professionals by specialty and geography with a precision that print and television simply cannot match.

The shift toward digital is also changing the economics of pharma review advertising. When a brand runs a pan-India print campaign, the review cycle happens once and the material is published. Digital campaigns, by contrast, may involve dozens of creative variants — different messages for different HCP specialties, different formats for different platforms, different language versions for regional markets — each of which technically requires its own review pass. We have worked with a large pharma client based in Mumbai who was running a multi-city digital campaign across Delhi, Bangalore, and several Tier 2 cities in Maharashtra; the campaign involved 47 distinct creative assets, and the MLR review process, which had not been planned for this volume, added nearly three weeks to the launch timeline and cost the brand an estimated ₹18 lakh in delayed media value.

The programmatic advertising opportunity in pharma is real and growing, but it comes with its own review complexity. Programmatic buying involves real-time ad serving across thousands of publisher sites, which means that the review process needs to account not just for the creative content but also for the placement context — a pharma ad appearing on a news site next to a story about drug side effects, for instance, creates a brand safety issue that the MLR review process is not always structured to anticipate. At SmartAds, we have developed a placement whitelist and blacklist framework specifically for pharma digital marketing India clients, which is reviewed and updated quarterly in line with changes in the publisher landscape.

What Are the Most Common Violations in Indian Pharma Advertising Review?

The violations that most frequently surface during pharma review advertising processes in India fall into a handful of recurring categories, and the pattern is consistent enough that we have come to think of them as structural blind spots rather than individual errors. The most common is the use of superlative claims — "the most effective", "the fastest-acting", "the only product that" — which are prohibited under both the DMRA 1954 and the ASCI guidelines unless supported by robust, peer-reviewed clinical evidence that has been cited in the material itself. Digital advertising formats, with their character limits and visual-first design conventions, are particularly prone to this violation because creative teams are often working to compress a complex message into a six-second video or a 300x250 banner.

The second most common violation involves the fair balance principle — specifically, the failure to present risk and side-effect information with the same prominence as benefit claims. In print, this is relatively straightforward to manage; in digital advertising, where formats are dynamic and screen sizes vary enormously, the fair balance principle creates genuine design challenges. A video ad that devotes 25 seconds to efficacy claims and three seconds of small-print text to side effects is technically non-compliant, even if all the information is technically present. We have seen this backfire when brands have used social media stories — which auto-advance and do not allow the viewer to pause — for prescription drug adjacent content, where the risk information disappears before most viewers have had time to read it.

Misleading advertisements involving patient testimonials are the third major category. The DMRA 1954 prohibits testimonials for certain drug categories, and the ASCI guidelines require that any testimonial — including those from healthcare professionals — be genuine, verifiable, and not misleading. In the era of influencer marketing and healthcare influencer content, this has become a significant review challenge; the ASCI influencer guidelines for health and wellness 2023 require that sponsored healthcare content be clearly labelled, that claims be substantiated, and that the influencer's credentials be accurately represented. Brands that have used healthcare influencers without running their content through the MLR review process have found themselves on the wrong end of ASCI complaints, which are now resolved publicly and searchable online — a reputational risk that is often underestimated.

How Can Pharma Companies Build an Audit-Ready Advertising Review System?

Building an audit-ready pharma review advertising system is less about adding more approval steps and more about designing the process so that every decision is documented, traceable, and defensible. The foundation is a claims library — a centralised, version-controlled repository of approved promotional claims, each linked to its supporting clinical reference and its MLR review approval record. When a new campaign is briefed, the creative and medical teams work from the claims library rather than generating new claims from scratch; this single practice, in our experience, reduces the MLR review cycle by somewhere between 30% and 50% because the review panel is evaluating execution rather than re-adjudicating claims.

Platforms like Veeva PromoMats have become the industry standard for managing this kind of audit-ready documentation in larger pharmaceutical organisations; the system tracks every version of every promotional material, records who reviewed it and when, and maintains the link between the approved material and its supporting references. For mid-sized Indian pharma companies that may not have the budget or infrastructure for Veeva PromoMats, the same principles can be applied using structured workflows in project management tools, provided that the documentation discipline is enforced consistently. The audit-ready requirement under UCPMP 2024 means that the self-declaration of UCPMP compliance needs to be backed by records that can be produced on request — which makes the documentation infrastructure a regulatory necessity, not just an operational convenience.

What a lot of people miss is that audit-readiness also applies to media placement records, not just creative content. A pharma company that can produce the approved creative but cannot demonstrate where and when it ran — which publisher sites, which audience segments, which geographic markets — is not fully audit-ready under the current regulatory expectations. At SmartAds, we provide our pharma clients with a campaign placement log as a standard deliverable, which records every impression-level placement decision and can be cross-referenced with the approved creative record in the event of a regulatory inquiry.

Technology Tools That Support Audit-Ready Pharma Review

MLR compliance automation tools have matured significantly in the past two years, and the Indian market is beginning to see adoption of AI-assisted review workflows that can flag potential violations before materials reach the human review panel. These tools — which typically use natural language processing to identify superlative claims, missing fair balance language, and prohibited therapeutic categories — do not replace the MLR review panel but they meaningfully reduce the volume of back-and-forth revisions that slow the process down. The time saving is real; we have seen clients reduce their average review cycle from 21 days to somewhere in the ballpark of 12 days after implementing an AI-assisted pre-screening step, which in a competitive launch window can be the difference between being first to market and being second.

What Role Does ASCI Play in Reviewing Pharmaceutical Advertisements in India?

The Advertising Standards Council of India occupies a distinctive position in the pharma review advertising ecosystem because it operates as a self-regulatory body rather than a statutory authority — but its decisions carry significant practical weight. ASCI reviews pharmaceutical advertisements in response to complaints from consumers, competitors, or its own monitoring programme, and upheld complaints are published on its website and reported in the trade press, which creates a public record of non-compliance that can affect brand reputation well beyond the immediate campaign. The ASCI complaints process has accelerated considerably since the introduction of its ASCI SURE platform, which allows complaints to be filed and tracked online.

ASCI's pharmaceutical advertising guidelines require that all health claims be truthful, not misleading, and substantiated by competent and reliable scientific evidence. For OTC drug advertising — which is the category most visible to general consumers — ASCI applies particular scrutiny to claims of efficacy, speed of action, and superiority over alternatives. The ASCI guidelines also address the presentation of healthcare professionals in advertising; an actor in a white coat implying medical endorsement is treated differently from a genuine HCP making a substantiated claim, and the review standards for each are distinct. ASCI's 2023 influencer guidelines for health and wellness have extended this scrutiny to social media marketing for pharma, requiring that healthcare influencers who are paid to promote products disclose their commercial relationship and ensure that their content has been reviewed for accuracy.

To be fair, ASCI does not have the power to impose fines or criminal penalties — those enforcement mechanisms sit with the CDSCO, the CCPA, and the courts under the DMRA 1954 and the Consumer Protection Act 2019. But an ASCI upheld complaint is frequently the trigger that brings a campaign to the attention of statutory authorities, which is why pharma companies treat ASCI review as a meaningful risk rather than a soft advisory process. The OPPI code also requires member companies to comply with ASCI guidelines, which means that for OPPI members, ASCI compliance is effectively mandatory rather than voluntary.

How Does Omnichannel Strategy Change the Pharma Review Advertising Process?

The shift toward omnichannel pharma marketing — where a single campaign runs simultaneously across paid search advertising, social media, programmatic display, email to HCPs, eDetailers for medical representatives, and WhatsApp pharma marketing for patient communities — has fundamentally changed the scope and complexity of the pharma review advertising process. In a single-channel world, the review panel evaluated one piece of material against one set of standards. In an omnichannel world, the same core message needs to be reviewed in multiple formats, for multiple audiences, against multiple regulatory frameworks, often simultaneously.

The review challenge is compounded by the fact that different channels have different regulatory expectations. Prescription drug advertising on digital platforms in India is governed by a strict prohibition on direct-to-consumer promotion — Schedule H drugs advertising to general consumers is not permitted, which means that a campaign for a prescription product needs to be structured so that the HCP-facing digital content is clearly separated from any patient awareness content, and the review process needs to verify that the targeting parameters are robust enough to prevent the HCP-facing material from reaching general consumers. Google Ads Healthcare Policy India adds another layer, restricting certain pharmaceutical advertising categories and requiring certification for others, which means that the campaign approval process for paid search advertising involves both internal MLR review and platform-level policy compliance.

WhatsApp pharma marketing deserves specific attention because it sits in a regulatory grey area that most pharma review advertising frameworks have not yet fully addressed. WhatsApp is used extensively by medical representatives to share promotional materials with HCPs in India — particularly in Tier 2 cities where face-to-face detailing is less frequent — but the materials shared via WhatsApp are subject to the same UCPMP 2024 and MLR review requirements as any other promotional channel. The challenge is that WhatsApp's informal, conversational format makes it easy for unapproved content to circulate, and the audit trail is far harder to maintain than it would be for a formal eDetailer deployment. We have found that pharma companies with strong audit-ready systems extend their content approval workflows explicitly to cover WhatsApp-shared materials, treating each approved PDF or video as a registered promotional item with its own review record.

What Are the Best Practices for HCP-Facing vs. Patient-Facing Pharma Ads in India?

The distinction between HCP-facing and patient-facing pharma advertising is not merely a matter of audience targeting — it is a fundamental regulatory divide that shapes every aspect of the review process, from the claims that can be made to the channels that can be used to the level of technical detail that is appropriate. HCP-facing advertising — which includes eDetailers, journal advertising, CME sponsorship advertising, and digital content targeted to healthcare professionals by specialty — is permitted to include clinical data, comparative efficacy information, and dosing guidance that would be inappropriate and potentially illegal in consumer-facing formats.

Patient-facing pharma advertising in India is largely restricted to OTC drug advertising and patient awareness campaigns for conditions rather than specific prescription products. The DMRA 1954 prohibits direct-to-consumer advertising for a range of conditions and drug categories, and the regulatory expectation is that patient awareness content will focus on disease education, treatment-seeking behaviour, and general health information rather than product promotion. The review process for patient-facing content is therefore evaluated against a different standard — one that prioritises clarity, accessibility, and the absence of misleading health claims over clinical precision. A patient awareness campaign that uses technical medical terminology without adequate explanation may be reviewed as potentially misleading even if every claim is scientifically accurate.

The practical implication for campaign planning is that HCP-facing and patient-facing digital campaigns should be developed, reviewed, and deployed as separate workstreams, even when they are part of the same brand campaign. We worked with a mid-sized pharma company that was running a dual-audience campaign for a diabetes management product — one stream targeting endocrinologists and general practitioners through programmatic advertising on medical publisher sites, and a parallel patient awareness stream running on general health and wellness platforms. By keeping the two review tracks entirely separate, with different claim sets, different creative briefs, and different MLR review submissions, the campaign cleared approval in under two weeks — which was significantly faster than the same client's previous campaigns, where the HCP and patient content had been reviewed together and the panel had struggled to apply a consistent standard.

How Are AI and Automation Transforming Pharma Review Advertising in India?

The application of artificial intelligence to the pharma review advertising process is one of the more genuinely consequential developments in Indian pharma marketing over the past two years, and the adoption curve is steeper than most people outside the industry realise. AI-assisted MLR compliance automation tools can now scan promotional materials — including digital banners, video scripts, eDetailer content, and social media copy — against a rules engine that reflects the current UCPMP 2024 requirements, ASCI guidelines, and the company's own approved claims library, flagging potential violations before the material reaches the human review panel. The result is that the human reviewers spend their time on genuinely ambiguous cases rather than catching basic errors, which compresses the overall review cycle considerably.

The more sophisticated implementations of MLR compliance automation also include version control and audit trail generation as automatic outputs, which directly supports the audit-ready documentation requirement under UCPMP 2024. Veeva PromoMats, which is the most widely deployed platform in this space among large multinational pharma companies operating in India, integrates content management, review workflow, and audit trail generation in a single system; Indian pharma companies that have implemented it report meaningful reductions in review cycle time and in the volume of compliance incidents. The platform is not inexpensive, and it requires significant configuration to reflect Indian regulatory requirements specifically — which is a gap that some implementation partners have not adequately addressed.

Here's where it gets interesting: AI is also beginning to be applied to the monitoring side of pharma review advertising — specifically, to scanning digital channels for non-compliant promotional content that may have been published without going through the review process. Several large pharma companies have deployed social listening tools configured to flag posts, comments, and influencer content that makes claims about their products, triggering a review process for content that the company did not originate. This is particularly relevant in the context of the ASCI influencer guidelines for health and wellness 2023, where a pharma brand can be held responsible for influencer content that was not properly reviewed and disclosed, even if the brand did not directly commission the specific post.

Frequently Asked Questions About Pharma Review Advertising in India

Q: What is pharma review advertising in India and how does the approval process work?

Pharma review advertising in India refers to the process by which pharmaceutical promotional materials are evaluated for regulatory compliance, scientific accuracy, and ethical appropriateness before they are published on any channel — digital or otherwise. The approval process typically involves two parallel tracks: an internal MLR review conducted by the company's own medical, legal, and regulatory panel, and compliance with external frameworks including UCPMP 2024, ASCI guidelines, and the DMRA 1954. For digital advertising specifically, the process also involves platform-level policy compliance — Google Ads Healthcare Policy India, for instance, has its own certification requirements for certain pharmaceutical advertising categories. The end-to-end process, from creative brief to live campaign, typically takes somewhere between two and six weeks depending on the complexity of the material and the efficiency of the internal review workflow.

Q: What are the key regulations governing pharmaceutical advertising review in India in 2024–2025?

The regulatory landscape for pharmaceutical advertising review in India in 2024–2025 is governed by five primary frameworks operating simultaneously. The DMRA 1954 prohibits advertising for certain drug categories and medical conditions, and violations carry criminal penalties. The Drugs and Cosmetics Act 1940 governs drug approvals and the accuracy of drug-related claims. UCPMP 2024, issued by the Department of Pharmaceuticals, sets the code of conduct for pharmaceutical marketing practices including digital advertising. The ASCI guidelines govern advertising standards across all categories including pharma and healthcare. And the Consumer Protection Act 2019, enforced by the Central Consumer Protection Authority, provides an additional enforcement mechanism against misleading advertisements that affect consumers. For HCP-facing content, the NMC guidelines and the OPPI Code of Pharmaceutical Practices add further requirements.

Q: How does UCPMP 2024 change the review and approval process for pharma digital ads?

UCPMP 2024 extends the code's requirements explicitly to digital advertising formats, which the 2015 version did not adequately address. The key changes for digital ad review include the explicit application of the fair balance principle to digital formats — meaning that risk information must be presented with the same prominence as benefit claims even in short-form digital content; the requirement that all digital promotional materials be linked to an approved prescribing information document; and the self-declaration of UCPMP compliance requirement, which means that companies must maintain documentation demonstrating that each piece of promotional material has been reviewed and approved in accordance with the code. The 2024 version also tightens the rules around digital sampling, online CME sponsorship advertising, and the use of social media for HCP engagement, all of which feed into the review process.

Q: What is the MLR review process and why is it mandatory for Indian pharma advertising?

The MLR review process — Medical, Legal, Regulatory — is the internal approval mechanism through which pharmaceutical companies evaluate promotional materials before publication. It is not mandated by a single law as such; rather, it is the operational mechanism through which companies demonstrate compliance with the multiple regulatory frameworks that govern pharma advertising in India, including UCPMP 2024 and the DMRA 1954. Without a documented MLR review process, a company cannot demonstrate that its promotional materials have been evaluated for accuracy, legality, and ethical compliance — which exposes it to regulatory action from the CDSCO, ASCI complaints, and CCPA notices under the Consumer Protection Act 2019. The MLR review process is also the mechanism through which the self-declaration of UCPMP compliance is generated and evidenced.

Q: What types of pharmaceutical advertisements are prohibited or restricted under the DMRA 1954?

The Drugs and Magic Remedies Objectionable Advertisements Act 1954 prohibits advertising — in any medium, including digital — for drugs or remedies that claim to prevent, cure, or mitigate a specified list of conditions, which includes cancer, epilepsy, sexual disorders, infertility, and several other categories. The act also prohibits advertisements that make false claims about a drug's composition, efficacy, or safety; advertisements that imply government endorsement that has not been given; and advertisements that use misleading visual representations of the drug's effects. For digital advertising, these prohibitions apply to display ads, video content, social media posts, paid search advertising, and any other digital format. Violations of the DMRA 1954 carry criminal penalties including imprisonment, which is why the act is taken seriously in the MLR review process even by companies that might be more casual about softer regulatory frameworks.

Q: Can prescription drugs (Schedule H) be advertised on digital platforms in India?

Schedule H drugs advertising directly to consumers on digital platforms is not permitted under Indian pharmaceutical regulations. Schedule H drugs — which require a prescription and are listed under the Drugs and Cosmetics Act 1940 — may not be promoted to the general public through any medium, including digital advertising. What is permitted is HCP-facing digital advertising for Schedule H products, provided it is targeted exclusively to healthcare professionals and goes through the appropriate MLR review and UCPMP 2024 compliance process. The targeting parameters for such campaigns need to be robust enough to prevent the content from reaching general consumers — which is a technical requirement that has implications for programmatic advertising and social media marketing for pharma. Patient awareness campaigns for conditions treated by Schedule H drugs are permissible, provided they focus on disease education rather than product promotion.

Q: What is ASCI's role in reviewing pharmaceutical and healthcare advertisements in India?

ASCI is India's self-regulatory advertising standards body, and it reviews pharmaceutical and healthcare advertisements in response to complaints or through its own monitoring programme. ASCI does not pre-approve advertisements before they are published; instead, it reviews complaints after publication and issues rulings that are publicly available. An upheld ASCI complaint requires the advertiser to modify or withdraw the non-compliant material, and persistent non-compliance can be referred to statutory authorities. ASCI's pharmaceutical advertising guidelines require that health claims be truthful, substantiated by scientific evidence, and not misleading. The 2023 influencer guidelines for health and wellness have extended ASCI's oversight to social media marketing for pharma, requiring disclosure of commercial relationships and substantiation of health claims made by healthcare influencers. ASCI also coordinates with the CCPA, which has the power to impose fines and penalties for misleading advertisements.

Q: How do pharma companies submit a self-declaration of UCPMP compliance for their advertising?

Under UCPMP 2024, pharmaceutical companies are required to submit a self-declaration of UCPMP compliance to the Department of Pharmaceuticals, certifying that their marketing practices — including advertising — conform to the code. The self-declaration is not a one-time submission; it is an ongoing certification that needs to be supported by internal audit records demonstrating that each piece of promotional material has been reviewed and approved in accordance with the code's requirements. For digital advertising specifically, this means maintaining a documented record of the MLR review process for each campaign, including the review panel's approval, the supporting clinical references, and the final approved creative. Companies that cannot produce this documentation on request are at risk of being found non-compliant, even if the advertising content itself is unobjectionable.

Q: What are the penalties for publishing non-compliant pharmaceutical advertisements in India?

The penalties for non-compliant pharmaceutical advertising in India vary by the regulatory framework under which the violation is prosecuted. Under the DMRA 1954, violations can result in imprisonment of up to six years and fines; repeat offences carry higher penalties. Under the Consumer Protection Act 2019, the Central Consumer Protection Authority can impose fines of up to ₹10 lakh on manufacturers and ₹2 lakh on endorsers for misleading advertisements, with higher penalties for repeat violations. ASCI upheld complaints require modification or withdrawal of the non-compliant material, and the public record of the complaint can have significant reputational consequences. CDSCO can take action under the Drugs and Cosmetics Act 1940 for violations involving drug claims, including suspension of drug approvals in serious cases. The cumulative risk across these frameworks makes non-compliance a genuinely serious financial and reputational exposure.

Q: How long does a typical pharma advertising review cycle take in India, and how can it be shortened?

A typical pharma advertising review cycle in India takes somewhere between two and six weeks, depending on the complexity of the material, the efficiency of the internal MLR review process, and the volume of materials being reviewed simultaneously. Simple OTC drug advertising materials with straightforward claims can clear review in as little as five to seven working days; complex HCP-facing campaigns involving clinical data, comparative claims, or multiple digital formats can take four to six weeks or more. The most effective ways to shorten the review cycle are to develop a pre-approved claims library that the creative team works from, to submit materials with complete reference documentation rather than adding it later, to use AI-assisted pre-screening tools to catch basic violations before the material reaches the human review panel, and to plan the review cycle as part of the campaign timeline rather than as a post-production step. In our experience at SmartAds, campaigns where the media plan and the compliance documentation are developed in parallel consistently clear review faster than those where compliance is treated as a final gate.

Q: What is the difference between HCP-facing and patient-facing pharma advertising review requirements in India?

HCP-facing pharma advertising — which targets healthcare professionals including doctors, pharmacists, and other clinicians — is permitted to include clinical data, dosing information, comparative efficacy claims, and technical medical content, provided it has cleared the MLR review process and complies with UCPMP 2024. Patient-facing pharma advertising is subject to stricter restrictions; it is largely limited to OTC drug advertising and disease awareness campaigns, and it may not promote prescription drugs directly to consumers. The review standards for patient-facing content are evaluated against a consumer protection lens — clarity, absence of misleading claims, and accessibility of risk information — rather than a clinical accuracy lens. The two types of content should be reviewed separately, with different claim sets and different review criteria, even when they are part of the same brand campaign.

Q: How are influencer marketing and pharma advertising reviews regulated by ASCI in India?

The ASCI influencer guidelines for health and wellness 2023 require that healthcare influencers who are paid to promote pharmaceutical products or health services disclose their commercial relationship clearly and prominently in every piece of sponsored content. The content itself must comply with the same advertising standards that apply to conventional pharma advertising — claims must be substantiated, risk information must be presented fairly, and the influencer's credentials must be accurately represented. Pharma companies are responsible for ensuring that influencer content has been reviewed for compliance before it is published, which means that influencer posts should go through the MLR review process in the same way as any other promotional material. The ASCI monitoring programme actively scans social media for non-compliant healthcare influencer content, and complaints can be filed by anyone — including competitors.

**Q: What is the 'fair balance' principle and how does it apply